Aethlon Medical (AEMD) Corporate presentation summary

Investment highlights and strategic focus

• Developing the patented Hemopurifier® blood purification device targeting cancer, viral diseases, and organ transplantation.

• Early clinical trials show clearance of viruses and extracellular vesicles (EVs) in vitro and in patients.

• Two FDA Breakthrough Device designations for oncology and viral indications.

• Ongoing and planned clinical trials in the US, Australia, and India, including COVID-19 studies.

• Broad patent portfolio with protection extending to 2044 if pending applications are granted.

Hemopurifier® technology and mechanism

• Proprietary hollow-fiber plasma separator with affinity resin captures mannosylated nanoparticles, including viruses and exosomes.

• Compatible with existing dialysis and CRRT infrastructure.

• Demonstrated safety in 164 sessions across 38 patients.

• Designed to clear tumor-derived EVs and life-threatening viruses from blood.

Oncology program and clinical evidence

• Rationale for removing tumor-derived EVs includes reducing metastasis, immune evasion, and therapy resistance.

• In vitro studies show 92-99% clearance of cancer-derived EVs.

• In vivo evidence of exosome and microRNA removal in patients, including those with COVID-19.

• Oncology clinical trials underway in Australia and India, focusing on patients post anti-PD-1 therapy.